SPOTLIGHT -
April 3rd 2024
This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.
April 2nd 2024
Have you checked out the latest Translating Research Into Practice column? Let us know!
March 30th 2024
The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.
March 16th 2024
From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.
March 8th 2024
Alzheimer disease treatment donanemab will be delayed as the FDA plans to convene a committee meeting to evaluate the phase 3 Trailblazer-Alz 2 trial.